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Appendix: Bayesian hierarchical models using R and JAGS  
Use of Bayesian models  
Just Another Gibbs Sampler (JAGS) (Plummer, 2003) was used for analysis of Bayesian hierarchical 
models using Markov Chain Monte Carlo Gibbs sampling methods (Casella and George, 1992).  
Choice of prior distributions  
“Noninformative” or “vague” priors were chosen that had minimal impact on the posterior 
distribution were chosen. Vague Normally distributed priors were used for estimated means of 
parameters of interest, with a mean of zero and precision 0.001. Vague priors were also applied to 
the standard deviation of estimated variance parameters by using Uniform prior distributions, as 
recommended by Gelman and Pardoe (2006), restricted to the range (0, 10) in order to avoid 
negative or unrealistically large values of the standard deviation around the estimated trends in each 
model.   
Model convergence and summary of the posterior distribution 
The coda package in R (Plummer and others, 2003) was used to assess model convergence and to 
summarise the sample posterior distribution for each parameter. The Heidelberger-Welche and 
Raftery-Lewis diagnostic tests (Plummer and others, 2003) were used to determine that an adaptive 
phase and burn in of 1000 and 500 iterations, respectively, were suitable for all models. Each model 
was run for 100,000 iterations with every 5th iteration retained (i.e. a thin of 5), resulting in a 
posterior sample size of 20,000 iterations. Three separate chains were used to assess stability in the 
estimates (Brooks, 1998). Overdispersed initial values were chosen for each chain (Gelman and 
Rubin, 1992). The Gelman-Rubin diagnostic was used to identify lack of convergence using multiple 
parallel chains. Convergence, mixing of chains and autocorrelation were assessed visually. Trace 
plots were examined to ensure that chains were mixing appropriately by plotting the sampled values 
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for each iteration in each chain. Density plots of posterior distributions and plots of the 
autocorrelation values for each parameter and each chain were also evaluated. 
Supplementary Figure 1 shows the trace, density and autocorrelation plot for the estimated annual 
yearly European trend in spina bifida from a hierarchical model for NTDs, as an example of a 
parameter with good mixing of chains, convergence and low autocorrelation. Each chain is drawn in 
a different colour (pink, green or blue). Supplementary Figure 2 shows the trace, density and 
autocorrelation plot for the intercept of the trend in spina bifida from a hierarchical model which 
also including registry as a random effect, as an example of a parameter with poor mixing of chains, 
lack of convergence and very high autocorrelation. 
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Supplementary table 1: Summary of model fit characteristics for hierarchical models 
Group of anomalies: NTDs Autosomal trisomy CHDs 
CHDs, with severity 
grouping 
Digestive system 
Mean Deviance 223 260 1223 1149 523 
Penalty 9 15 75 75 29 
DIC (penalised deviance) 231 275 1223 1224 552 
Multivariate Potential Scale Reduction 
Factor 
1.02 1.00 1.00 1.00 1.00 
Mean of anomaly trends (95% PCI) -0.004 (-0.12, 0.10) 0.02 (-0.04, 0.07) -0.001 (-0.01, 0.01) -0.001 (-0.15, 0.15) 0.002 (-0.02, 0.02) 
SD of anomaly trends (95% PCI) 0.07 (0.001, 0.51) 0.03 (0.0004, 0.22) 0.02 (0.01, 0.04) 0.08 (0.001, 0.53) 0.02 (0.001, 0.05) 
SD for overdispersion parameter (95% 
PCI) 
0.03 (0.001, 0.08) 0.04 (0.01, 0.08) 0.08 (0.06, 0.11) 0.08 (0.06, 0.11) 0.08 (0.01, 0.13) 
Correlation between anomaly 
intercepts and slopes 
1 1 -0.47 0.12 0.99 
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Supplementary figure 1. Example of a trace (A), density (B) and autocorrelation (C) plot for a 
parameter with good convergence and mixing of chains and low autocorrelation  
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Supplementary figure 2. Example of a trace (A), density (B) and autocorrelation (C) plot for a 
parameter with lack of convergence, poor mixing of chains and very high autocorrelation. 
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Abstract 58 
Background: Surveillance of congenital anomalies is important to identify potential teratogens. 59 
Despite known associations between different anomalies, current surveillance methods examine 60 
trends within each subgroup separately. We aimed to evaluate whether hierarchical statistical 61 
methods that combine information from several subgroups simultaneously would enhance current 62 
surveillance methods using data collected by EUROCAT, a European network of population-based 63 
congenital anomaly registries. 64 
Methods: Ten year trends (2003 to 2012) in 18 EUROCAT registries over 11 countries were analysed 65 
for the following groups of anomalies: neural tube defects, congenital heart defects, digestive system 66 
and chromosomal anomalies. Hierarchical Poisson regression models that combined related 67 
subgroups together according to EUROCAT’s hierarchy of subgroup coding were applied. Results from 68 
hierarchical models were compared to those from Poisson models that consider each congenital 69 
anomaly separately. 70 
Results: Hierarchical models gave similar results as those obtained when considering each anomaly 71 
subgroup in a separate analysis. Hierarchical models that included only around three subgroups 72 
showed poor convergence and were generally found to be over-parameterised. Larger sets of anomaly 73 
subgroups were found to be too heterogeneous to group together in this way. 74 
Conclusions: There were no substantial differences between independent analyses of each subgroup 75 
and hierarchical models when using the EUROCAT anomaly subgroups. Considering each anomaly 76 
separately therefore remains an appropriate method for the detection of potential changes in 77 
prevalence by surveillance systems. Hierarchical models do, however, remain an interesting 78 
alternative method of analysis when considering the risks of specific exposures in relation to the 79 
prevalence of congenital anomalies, which could be investigated in other studies. 80 
Keywords: congenital anomalies, trends, prevalence, hierarchical models 81 
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Introduction 82 
Congenital anomalies are structural or functional abnormalities that are present at birth. They are a 83 
leading worldwide cause of fetal and infant death, chronic illness and disability in childhood; a diverse 84 
group of disorders for which only around 50% can be linked to a specific known cause or risk factor 85 
(World Health Organization, 2014). Causes of congenital anomaly include a wide range of both genetic 86 
and environmental factors such as maternal age, nutritional status or exposure to certain medications. 87 
It is important to identify risk factors for congenital anomalies, in particular the early identification of 88 
new potentially teratogenic exposures. Following the Thalidomide disaster, congenital anomaly 89 
registries were established worldwide in order to facilitate surveillance and research into the causes 90 
of birth defects (Khoury and others, 1994; McBride, 1961). A European network of such population-91 
based registries, EUROCAT, provides important epidemiologic information on congenital anomaly by 92 
collecting data on over 1.7 million births from 43 registries in 23 countries across Europe (EUROCAT, 93 
2016). EUROCAT annually monitors the birth prevalence of specific anomalies in order to detect new 94 
or continuing trends, identifying new potentially teratogenic exposures and evaluating the 95 
effectiveness of primary prevention policies (Dolk, 2005).  96 
Surveillance of congenital anomalies is often performed using defined sets of subgroups, such as the 97 
EUROCAT anomaly subgroups (EUROCAT, 2005). Many of these subgroups overlap, for example the 98 
congenital heart defects (CHD) subgroup includes further subgroups such as ventricular septal defects, 99 
atrial septal defects and tetralogy of Fallot (ToF). Despite known relationships amongst many of the 100 
subgroups, current surveillance methods examine trends, clusters or associations between risk factors 101 
and anomalies within each subgroup separately (EUROCAT, 2015; Loane and others, 2011b). Relevant 102 
information on relationships between anomalies across the different subgroups is therefore not 103 
currently being incorporated in surveillance analyses; hence it is possible that important associations 104 
or trends are not being detected by the current methods. Congenital anomaly surveillance methods 105 
that combine information from several subgroups simultaneously may enhance the analysis of any 106 
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particular anomaly by considering what is happening in related or similar anomalies. The aim of this 107 
paper is to evaluate whether hierarchical statistical methods that combine information from several 108 
subgroups within the same congenital anomaly group simultaneously increase the power to detect 109 
trends in congenital anomalies. 110 
Methods 111 
EUROCAT dataset 112 
This study is based on routinely collected EUROCAT data from 18 full member registries in 11 European 113 
countries: Austria (Styria registry), Belgium (Antwerp and Hainaut), Denmark (Odense) France (Paris 114 
and Isle de la Reunion), Germany (Saxony-Anhalt) Ireland (Cork & Kerry and Dublin), Italy (Tuscany) 115 
Netherlands (Northern Netherlands), Spain (Basque Country), Switzerland (Vaud) and the UK (East 116 
Midlands & South Yorkshire, Northern England, Thames Valley, Wales and Wessex). Data was 117 
extracted from the EUROmediCAT central database in February 2015, including only registries with a 118 
total prevalence of all anomalies greater than 2% and available data for at least nine years of the ten 119 
year period from 01 January 2003 to 31 December 2012. All coding was done according to EUROCAT 120 
guide 1.3 (www.eurocat-network.eu/content/EUROCAT-Guide-1.3.pdf) (EUROCAT, 2005), which uses 121 
a hierarchy of codes to classify all cases of non-minor congenital anomaly into 89 EUROCAT anomaly 122 
subgroups. EUROCAT anomaly subgroups are grouped in a hierarchical structure, with the highest 123 
level being the major organ groups, within which there are further classes. Spina bifida, for example, 124 
is in the neural tube defects (NTD) subgroup, which is within the Nervous System group of anomalies. 125 
A case may be counted only once in each of the lowest level EUROCAT subgroups, but if it has multiple 126 
anomalies it will be counted in multiple subgroups. Cases with genetic conditions (genetic syndromes/ 127 
microdeletions, teratogenic syndromes with malformations, or chromosomal anomalies) were 128 
excluded from all analyses of non-chromosomal anomaly. Data are collected for all birth outcomes, 129 
including live and still births and terminations of pregnancy for fetal anomaly. Further details regarding 130 
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the registries, methods of case ascertainment and data collection and processing are described 131 
elsewhere (Boyd and others, 2011; EUROCAT, 2005; Greenlees and others, 2011). 132 
Statistical Methods 133 
The most recent ten years of data available were assessed for changes in prevalence for the following 134 
groups of anomalies: NTDs, autosomal chromosome anomalies, CHDs and digestive system anomalies. 135 
Poisson regression was used to model prevalence rates for the number of congenital anomaly cases 136 
each year, with the log total births included as an offset to account for the differing population size 137 
each year. Estimated average yearly ten year trends in prevalence obtained from individual models 138 
(separate Poisson models for each anomaly subgroup with no information sharing between anomaly 139 
subgroups) were compared to those obtained from hierarchical models (one Poisson model fitting 140 
related anomaly subgroups simultaneously with sharing of information between anomaly subgroups). 141 
For CHDs there are sixteen standard subgroups (EUROCAT, 2005) that have previously been grouped 142 
using a hierarchical severity ranking according to perinatal mortality rates in non-chromosomal cases, 143 
formed of three ordered groups from severity I (high perinatal mortality) to severity III (low perinatal 144 
mortality) (EUROCAT, 2009) (Table 1). A two level hierarchy that includes the grouping of CHDs by 145 
these severity subgroups was also considered. A data-level variance component was used to directly 146 
model potential overdispersion in the data for hierarchical models (Gelman and Hill, 2007).  Models 147 
were also repeated with the inclusion of a term to take account of the random effects of registry. All 148 
statistical analyses were conducted in R (R Development Core Team, 2008). Markov Chain Monte Carlo 149 
sampling methods were used to obtain estimates of variability around the random effects in 150 
hierarchical models by using Gibbs sampling (Casella and George, 1992) in the Bayesian analysis 151 
programme JAGS via the R package rjags (Plummer, 2003). Results from hierarchical models are 152 
presented as annual percentage changes in prevalence and their 95% posterior credible intervals 153 
(PCIs), which can be thought of as the Bayesian equivalent of 95% confidence intervals (CIs) and where 154 
we say there is a 95% probability that the true trend in prevalence lies within this interval. If the 95% 155 
8 
 
CI or PCI doesn’t include zero then we consider this a “statistically significant” average annual change 156 
in prevalence or a “signal”. The resulting estimates are only valid if convergence has occurred, which 157 
is assessed graphically and by using convergence diagnostics in the R package coda (Plummer and 158 
others, 2003). Further details on the use of the Bayesian hierarchical models in JAGs can be found in 159 
the Appendix. 160 
Results 161 
A total of 103,507 cases of congenital anomaly (81,147 cases excluding genetic conditions) were 162 
available for analysis from a combined population of 4,097,142 births over 18 registries during the 10 163 
year study period. Trends were assessed in 4,167 NTD, 13,358 chromosomal, 25,273 CHD and 7,683 164 
digestive system anomaly cases (Table 1). The rarest subgroup included in these analyses was the 165 
digestive system anomaly annular pancreas, with only 57 cases in the combined population over the 166 
ten years giving an estimated total prevalence of 0.1 cases per 10,000 births. The most common 167 
anomaly subgroup was the CHD ventricular septal defect, with an estimated total prevalence of almost 168 
28 cases per 10,000 births (Table 1).  169 
Models for neural tube defects 170 
There were no changes in prevalence for any of the NTD subgroups, with estimated average annual 171 
trends remaining very similar for individual and hierarchical models and 95% CIs and PCIs including 172 
zero (no change) for all estimates (Figure 1). There was some “shrinkage” in the estimates towards 173 
the group mean in the hierarchical model, in particular for encephalocele, although this estimated 174 
trend was not significant in either model. 175 
Models for chromosomal anomalies 176 
In individual models, an increasing trend of 1.7% (95% CI: 0.7% to 2.6%) and 1.8% (95% CI: 0.4% to 177 
3.1%) per year on average was observed for Down and Edwards syndrome, respectively (Figure 2), but 178 
there was no significant change in prevalence of Patau syndrome. Trends in prevalence were similar 179 
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when combining the three anomalies together in a hierarchical model; the estimated trend for Patau 180 
syndrome increased slightly towards the average of the three trends but the 95% PCI still included 181 
zero (Figure 2). 182 
Models for congenital heart defects 183 
Of all cases with CHD, 85.5% were counted in one of the three EUROCAT severity groups for CHDs, 184 
excluding those with patent ductus arteriosus in term infants as well as a number of other CHDs that 185 
are not assigned a specific subgroup code according to EUROCAT’s coding hierarchy. In individual 186 
models, decreasing trends for atrial septal defect (ASD) and pulmonary valve stenosis (PVS), and an 187 
increasing trend for ToF were observed (Figure 3). When using a hierarchical model that combined all 188 
CHDs (Figure 3), the estimated trends for PVS and ToF attenuated towards the null. The only significant 189 
change in prevalence in a hierarchical model was for ASD, which attenuated slightly to 3.0% on average 190 
from the estimated 4.1% in an individual model. Average annual changes in prevalence for the other 191 
CHD subgroups were a mix of increasing and decreasing trends, none of which were statistically 192 
significant in either model. When including severity subgroup as an additional level in a hierarchical 193 
model for CHDs (Figure 3), the trends for ASD and PVS remained significant, with estimated average 194 
changes in prevalence very similar to those obtained in individual models. The increasing trend for ToF 195 
was not statistically significant when grouping all CHDs together, whether including the severity 196 
grouping or not. 197 
Models for digestive system anomalies 198 
There were no significant trends in prevalence for any of the digestive system subgroups for individual 199 
or hierarchical models (Figure 4), with estimated trends in the hierarchical model generally 200 
attenuating towards the mean of the estimated trends across the eight subgroups, which was again 201 
close to the null value of no trend. Subgroups that were less precisely estimated were more affected 202 
by the information in other subgroups, giving more marked differences in estimated trends in the less 203 
common anomalies for individual models compared to a hierarchical model. 204 
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Model assessment for hierarchical models 205 
Parameters for hierarchical models that included a reasonable number of subgroups (i.e. eight or more 206 
for the digestive system anomalies) displayed good convergence. Hierarchical models for smaller 207 
groups of anomalies (e.g. models for NTDs and autosomal anomalies including only three subgroups) 208 
showed poor convergence due to over parameterisation in the model. Further details on model 209 
diagnostics for hierarchical models are given in the appendix. 210 
Including a registry effect 211 
All models were repeated with the inclusion of a random effect for registry to assess the effect of 212 
accounting for differences at the registry level. The estimated trends in prevalence of each anomaly 213 
subgroup remained very similar to those described above when including the effect of registry for all 214 
models (data not shown). Hierarchical models that included a registry effect, in particular those with 215 
only a small number of subgroups, demonstrated an overall lack of convergence. 216 
Discussion 217 
For all examples of congenital anomaly subgroups considered in these analyses, estimated trends in 218 
prevalence were similar whether considering anomalies separately (individual models) or together 219 
(hierarchical model). Identified trends were consistent with other studies. Increasing trends in 220 
chromosomal anomalies were observed, which are known to be due to maternal age and changes in 221 
prenatal screening practices (Cocchi and others, 2010; Loane and others, 2013). NTD prevalence 222 
remained stable in EUROCAT registries, as has been observed elsewhere (Botto and others, 2006; 223 
Khoshnood and others, 2015). This might be explained by the lack of folic acid fortification in Europe 224 
and poor uptake of folic acid supplementation; in the UK, for example, under 30% of women took folic 225 
acid prior to their pregnancy in 2011–2012 (Bestwick and others, 2014). Prevalence in three of the 226 
digestive system anomaly subgroups was found to be significantly increasing in the latest EUROCAT 227 
statistical monitoring report (EUROCAT, 2015). A similar estimated increase in prevalence in these 228 
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three subgroups was observed here, although these trends did not reach statistical significance in 229 
independent models due to the smaller number of registries included. Increases in the prevalence of 230 
the CHDs single ventricle (severity group I), ToF and atrioventricular septal defect (severity group II) 231 
were consistent with previous findings (EUROCAT, 2015). Estimated decreases in prevalence of ASD 232 
and PVS, however, were not consistent with those observed in other studies, where either no 233 
significant changes or increasing trends have been observed (EUROCAT, 2015; van der Linde and 234 
others, 2011). Published prevalence estimates in CHDs are known to vary substantially due to differing 235 
definitions of cases across studies, and it is likely that the differences in estimated trends here reflect 236 
changes in reporting for these anomalies (in recent years EUROCAT have focused on only reporting 237 
ASD cases that have been confirmed after 6 months of age) or differing prenatal screening practices 238 
in this particular set of registries (Baardman and others, 2014; Garne and others, 2012; Hoffman and 239 
Kaplan, 2002). 240 
Hierarchical models have proven useful in the field of pharmacovigilance, where they have been used 241 
in the detection of potential adverse drug reactions (Berry and Berry, 2004; Crooks and others, 2012; 242 
Xia and others, 2011). Natural hierarchies in drug and adverse event coding have been used to group 243 
similar drugs or adverse events together, such that models for each drug-adverse event combination 244 
incorporate information from analyses of other similar drugs and adverse events (Prieto-Merino and 245 
others, 2011). In this paper, the same rationale was applied to congenital anomalies; however, the 246 
situation here was different compared to that for adverse drug reactions, where the hierarchical 247 
classification systems may provide more natural hierarchies than the grouping of anomalies according 248 
to the defined subgroups. Indeed, the EUROCAT subgroup coding hierarchy provides sets of anomalies 249 
that are too heterogeneous in practice to be grouped together when analysing changes in prevalence. 250 
This is because the “shrinkage”, a key feature of hierarchical models (Gelman and Hill, 2007) whereby 251 
the estimated trend for each subgroup is influenced towards the average trend over all subgroups in 252 
the model, will largely pull estimates towards the null if there is a mixture of increasing and decreasing 253 
trends, as was the case for CHD and digestive anomalies. It is possible, therefore, that potential 254 
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changes in prevalence in analyses of groups of anomalies such as these could actually be masked by 255 
hierarchical models. On the other hand, this shrinkage can help control estimates based on small 256 
counts by including information from the rest of the group. Moreover, this can be thought of as a 257 
natural “penalisation” considering that a hierarchical model is simultaneously looking for changes in 258 
prevalence in numerous subgroups, compared to individual models where this multiple testing aspect 259 
is not taken into account (and a number of false positive results are therefore likely). For a group 260 
where the mean trend across subgroups is close to the null, this penalisation will mean that the 261 
estimated trend is no longer a “signal” in the hierarchical model, for example as seen for the CHD ToF 262 
in severity group II (Figure 3). For a group where the mean trend is not so close to the null, however, 263 
this penalisation might actually lead to an increase in the strength and precision of a signal, for 264 
example for ASD in severity group III (Figure 3). Furthermore, the same signal might be reduced or 265 
enhanced depending on which grouping is used; for example, the trend in PVS is attenuated if 266 
considering all CHD groups together but maintained if also including the severity grouping in the 267 
hierarchical model (Figure 3). This highlights how the posterior distribution is sensitive to the prior 268 
information, which here is the way the groups have been defined. 269 
EUROCAT subgroups that were considered to be related, for example aetiologically similar or in the 270 
same organ system class, were still found to vary considerably in terms of their differing proportional 271 
yearly changes in prevalence. It is well known (Gelman and Hill, 2007; Greenland, 2000), and has been 272 
seen here in the case of NTDs and autosomal trisomy groups of anomalies,  that a random effects 273 
model with only three levels for the random effect parameter does not perform well, with such models 274 
showing poor convergence and over-parameterisation. There may be other larger groups of anomalies 275 
that are similar enough to be analysed together that were not considered here, and in fact there are 276 
known relationships between anomalies that lie within different groups of the EUROCAT hierarchy. In 277 
addition to NTDs, for example, there are a number of other anomalies across different body systems 278 
that are known to be sensitive to folate levels during pregnancy, including CHDs, clefts and limb 279 
reduction defects (Wilson and others, 2015). If there was evidence that folate levels had been 280 
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increasing in Europe, then it would have been useful to have analysed all these anomalies as a 281 
hierarchical model. However, from examining the NTDs alone here and in other studies, no such 282 
change has occurred in Europe and hence such models were not further investigated. Similarly, 283 
EUROCAT now includes a VATER/VACTERL association subgroup that comprises anomalies of the 284 
vertebra, anal atresia, CHDs, trachea-esophageal fistula, esophageal atresia, radial anomaly and limb 285 
defect, which are known to occur together more frequently than expected by chance. However, the 286 
heterogeneity of trends in just the CHD component of this subgroup indicates that hierarchical models 287 
are not likely to add any useful information to such an analysis. When examining congenital anomaly 288 
prevalence there are many factors that are likely to have an influence, such as reporting, case 289 
ascertainment or screening practices. Hierarchical models might be more relevant, then, when 290 
considering the risks of specific exposures in relation to prevalence of congenital anomalies. It would 291 
therefore be worthwhile investigating the application of hierarchical models in such situations, for 292 
example when looking at the risk of medications taken during the first trimester of pregnancy. 293 
Strengths and limitations of this study 294 
EUROCAT registries collect data that is ascertained from multiple sources and includes information on 295 
all major structural congenital and chromosomal anomalies (Boyd and others, 2011; Loane and others, 296 
2011a), providing high quality population-based data across multiple European countries and allowing 297 
the inclusion of a large number of congenital anomaly cases covering over four million births over ten 298 
years for this study. EUROCAT registries include information on cases of prenatal diagnosis followed 299 
by termination of pregnancy, enabling the inclusion of cases that would otherwise have gone 300 
undiagnosed, or unreported amongst spontaneous abortions or stillbirths. One potential limitation of 301 
this study is that it was not possible to include data from all of the EUROCAT member registries in 302 
these analyses, hence some trends that were seen in the latest statistical monitoring report did not 303 
reach statistical significance here, likely due to the smaller sample sizes included. However, it does not 304 
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seem likely that increasing the sample size would have improved the performance of hierarchical 305 
models. 306 
Conclusions 307 
In summary, the hierarchical models considered here demonstrated that sharing information between 308 
subgroups of anomalies can provide a sensible “penalisation”, helping to avoid false positive signals 309 
by shrinking the estimated trends towards the null when there is no evidence of other trends in the 310 
rest of the group, whilst maintaining signals of changes in prevalence when there are others in the 311 
group. Using the EUROCAT hierarchy of anomaly subgroups, however, presented no substantial 312 
differences between the independent analyses of each subgroup and hierarchical models. When using 313 
EUROCAT subgroups for analysis, therefore, considering each congenital anomaly separately remains 314 
an appropriate method for the detection of potential changes in prevalence by relevant surveillance 315 
systems. Hierarchical models do, however, remain an interesting and potentially useful alternative 316 
method of analysis when considering the risks of specific exposures in relation to the prevalence of 317 
congenital anomalies, and this could be investigated in other studies. 318 
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Table and figure legends 414 
Table 1. Total prevalence of selected groups and subgroups of congenital anomalies per 10,000 births, 415 
using data covering 4,097,142 births from 18 EUROCAT registries, 2003 to 2012. 416 
Figure 1. Estimated average annual trends in prevalence of neural tube defects with 95% Posterior 417 
Credibility Intervals.   418 
Figure 2. Estimated average annual trends in prevalence of chromosomal anomaly subgroups with 419 
95% Posterior Credibility Intervals.   420 
Figure 3. Estimated average annual trends in prevalence of congenital heart defect subgroups with 421 
95% Posterior Credibility Intervals.   422 
Figure 4. Estimated average annual trends in prevalence of digestive system subgroups with 95% 423 
Posterior Credibility Intervals.   424 
Table 1. Total prevalence of selected groups and subgroups of congenital anomalies per 10,000 births, 
using data covering 4,097,142 births from 18 EUROCAT registries, 2003 to 2012. 
Anomaly group and subgroup Total  casesa Prevalence (95% CI) 
Neural Tube Defects 4,167 10.2 (9.9, 10.5) 
Anencephaly 1,709 4.2 (4.0, 4.4) 
Encephalocele 430 1.0 (1.0, 1.2) 
Spina Bifida 2,028 4.9 (4.7, 5.2) 
Autosomal chromosome anomalies 13,358 32.6 (32.1, 33.2) 
Down syndrome / trisomy 21 9,854 24.1 (23.6, 24.5) 
Patau syndrome / trisomy 13 942 2.3 (2.2, 2.5) 
Edwards syndrome / trisomy 18 2,562 6.3 (6.0, 6.5) 
Congenital heart defects 25,273 61.7 (60.9, 62.4) 
Severity group I:                                              
Single ventricle 249 0.6 (0.5, 0.7) 
Tricuspid atresia and stenosis 286 0.7 (0.6, 0.8) 
Ebstein’s anomaly 212 0.5 (0.5, 0.6) 
Hypoplastic left heart 1,127 2.8 (2.6, 2.9) 
Hypoplastic right heart 205 0.5 (0.4, 0.6) 
Severity group II:                           
Common arterial truncus 233 0.6 (0.5, 0.6) 
Transposition of great vessels 1,467 3.6 (3.4, 3.8) 
Atrioventricular septal defect 838 2.0 (1.9, 2.2) 
Tetralogy of Fallot 1,187 2.9 (2.7, 3.1) 
Pulmonary valve atresia 425 1.0 (0.9, 1.1) 
Aortic valve atresia/stenosis 540 1.3 (1.2, 1.4) 
Coarctation of aorta 1,488 3.6 (3.4, 3.8) 
Total anomalous pulmonary venous return 299 0.7 (0.6, 0.8) 
Severity group III:                
Ventricular septal defect 11,262 27.5 (27.0, 28.0) 
Atrial septal defect 5,226 12.8 (12.4, 13.1) 
Pulmonary valve stenosis 1,850 4.5 (4.3, 4.7) 
Digestive system anomalies 7,683 18.8 (18.3, 19.2) 
Oesophageal atresia with or without tracheo-
oesophageal fistula  
890 2.2 (2.0, 2.3) 
Duodenal atresia or stenosis 377 0.9 (0.8, 1.0) 
Atresia or stenosis of other parts of small intestine 393 1.0 (0.9, 1.1) 
Ano-rectal atresia and stenosis 1,157 2.8 (2.7, 3.0) 
Hirschsprung’s disease 548 1.3 (1.2, 1.5) 
Atresia of bile ducts 122 0.3 (0.2, 0.4) 
Annular pancreas 57 0.1 (0.1, 0.2) 
Diaphragmatic hernia 1,030 2.5 (2.4, 2.7) 
a Including livebirths, stillbirths and terminations of pregnancy after prenatal diagnosis 
 
Figure 1. Estimated average annual trends in prevalence of neural tube defects with 95% Posterior 
Credibility Intervals.   
 
  
Figure 2. Estimated average annual trends in prevalence of chromosomal anomaly subgroups with 
95% Posterior Credibility Intervals.   
  
Figure 3. Estimated average annual trends in prevalence of congenital heart defect subgroups with 
95% Posterior Credibility Intervals.   
  
Figure 4. Estimated average annual trends in prevalence of digestive system subgroups with 95% 
Posterior Credibility Intervals.   
 
 
